RTW - Ticker AI Digest

RTW Venture Fund Ltd 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (RTW) 1
RTW 06:01
RTW Venture Fund Ltd
Monthly Valuation Update and Factsheet
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
RTW 09:01
RTW Venture Fund Ltd
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 2
RTW 06:01
RTW Venture Fund Ltd
Monthly Valuation Update and Factsheet
RTW 06:01
RTW Venture Fund Ltd
Monthly Valuation Update and Factsheet
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
RTW Biotech Opportunities Ltd released its monthly valuation update and factsheet for January 2026, highlighting key financial and operational developments. As of December 31, 2025, the company’s unaudited net asset value (NAV) per share was $2.45, a 4.2% decrease from the previous month, underperforming the Nasdaq Biotech Index (-1.9%) but outpacing the Russell 2000 Biotech Index (+0.5%). Since its launch in October 2019, the company has delivered an annualized NAV return of 14.5%.
**Portfolio Highlights**
Top holdings include PTC Therapeutics (11.6% of NAV), Corxel (6.2%), and Stoke Therapeutics (5.2%).
Top contributors to NAV in the period were Avidity (+9.5%), PTC (+5.1%), and Stoke (+4.9%), while detractors included Rocket (-3.9%) and Artios (-2.9%).
**Company Updates**
The company allocated an additional $15 million to NAV-accretive share buybacks, supplementing the existing $30 million program, following successful M&A transactions.
RTW Biotech was included in the FTSE 250 Index in December 2025, enhancing liquidity and investor awareness.
The company hosted its first retail shareholder webinar in December, presented by its chair and RTW Investments executives.
**Performance and Sector Outlook**
In Q4 2025, the company’s NAV returned +15.5%, underperforming the Russell 2000 Biotech Index (+29%) and Nasdaq Biotech Index (+17%).
The biotech sector rebounded in 2025, with indices outperforming the S&P 500 and Nasdaq, driven by reduced policy uncertainty, increased M&A activity ($105B in deals), and improved investor sentiment.
RTW Biotech remains optimistic for 2026, citing continued innovation, a strong financing environment, and further M&A opportunities.
**Recent Investment**
In December 2025, the company invested $5.9 million in Yarrow Bioscience, a clinical-stage biotech focused on autoimmune thyroid diseases, representing 0.7% of NAV. Yarrow is set to merge with VYNE Therapeutics in Q2 2026.
**Conclusion**
RTW Biotech Opportunities Ltd continues to focus on long-term capital growth, leveraging its expertise in the biopharmaceutical and medical technology sectors. Despite short-term NAV fluctuations, the company remains well-positioned to capitalize on the biotech sector’s recovery and emerging opportunities.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
RTW 06:01
RTW Venture Fund Ltd
Monthly Valuation Update and Factsheet
RTW 06:01
RTW Venture Fund Ltd
Corxel completes $287 million Series D-1 financing
RTW 09:01
RTW Venture Fund Ltd
Director/PDMR Shareholding
RTW 06:01
RTW Venture Fund Ltd
GSK to acquire RAPT Therapeutics
RTW 06:01
RTW Venture Fund Ltd
Boston Scientific to acquire Penumbra
RTW 06:01
RTW Venture Fund Ltd
Monthly Valuation Update and Factsheet
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
RTW Biotech Opportunities Ltd released its monthly valuation update and factsheet for January 2026, highlighting key financial and operational developments. As of December 31, 2025, the company’s unaudited net asset value (NAV) per share was $2.45, a 4.2% decrease from the previous month, underperforming the Nasdaq Biotech Index (-1.9%) but outpacing the Russell 2000 Biotech Index (+0.5%). Since its launch in October 2019, the company has delivered an annualized NAV return of 14.5%.
**Portfolio Highlights**
Top holdings include PTC Therapeutics (11.6% of NAV), Corxel (6.2%), and Stoke Therapeutics (5.2%).
Top contributors to NAV in the period were Avidity (+9.5%), PTC (+5.1%), and Stoke (+4.9%), while detractors included Rocket (-3.9%) and Artios (-2.9%).
**Company Updates**
The company allocated an additional $15 million to NAV-accretive share buybacks, supplementing the existing $30 million program, following successful M&A transactions.
RTW Biotech was included in the FTSE 250 Index in December 2025, enhancing liquidity and investor awareness.
The company hosted its first retail shareholder webinar in December, presented by its chair and RTW Investments executives.
**Performance and Sector Outlook**
In Q4 2025, the company’s NAV returned +15.5%, underperforming the Russell 2000 Biotech Index (+29%) and Nasdaq Biotech Index (+17%).
The biotech sector rebounded in 2025, with indices outperforming the S&P 500 and Nasdaq, driven by reduced policy uncertainty, increased M&A activity ($105B in deals), and improved investor sentiment.
RTW Biotech remains optimistic for 2026, citing continued innovation, a strong financing environment, and further M&A opportunities.
**Recent Investment**
In December 2025, the company invested $5.9 million in Yarrow Bioscience, a clinical-stage biotech focused on autoimmune thyroid diseases, representing 0.7% of NAV. Yarrow is set to merge with VYNE Therapeutics in Q2 2026.
**Conclusion**
RTW Biotech Opportunities Ltd continues to focus on long-term capital growth, leveraging its expertise in the biopharmaceutical and medical technology sectors. Despite short-term NAV fluctuations, the company remains well-positioned to capitalize on the biotech sector’s recovery and emerging opportunities.

AI Crunch

Single-Ticker AI Crunch
RTW signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for RTW Venture Fund Ltd. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full RTW AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for RTW on 2026-02-13.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
68506649600
Enterprise Value
374310432
Public Float
-
Broker Target
-
Shares Out
325223649
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
USD
ISIN
GG00BKTRRM22
Market
LSE - MAIN MARKET - SFS
Sector
Financial Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-30
Net Debt
-5986177.0
Cash
5986177.0
EPS
0.63
Net Income
245192677.0
Revenue
258013835.0
Enterprise Value
374310432
Trailing PE
0.0334
Forward PE
-
Price Sales TTM
19.8145
Price Book MRQ
0.7781
EV Revenue
2.6833
EV EBITDA
-

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.99
Institutions As Of
2025-07-03
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
4
Sale Director Dealing
0
Purchase TR1
1
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit RTW.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-02-13 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
RTW Venture Fund Ltd has fresh news flow feeding the chart narrative.
06:01 Today's Catalyst Monthly Valuation Update and Factsheet
AI Charts Studio
RTW Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-02-13 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast